# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

# FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report: March 16, 2009 (Date of earliest event reported)

# **DURECT CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 000-31615 (Commission File Number) 94-3297098 (IRS Employer Identification No.)

2 Results Way
Cupertino, CA 95014
(Address of principal executive offices) (Zip code)

(408) 777-1417

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.010ther Events

On March 16, 2009, DURECT Corporation, a Delaware corporation ("<u>DURECT</u>"), issued a press release announcing positive Phase IIb data from the TRANSDUR-Sufentanil clinical program. A copy of DURECT's press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

### **Item 9.01Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release of DURECT Corporation dated March 16, 2009

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## **DURECT Corporation**

Date: March 16, 2009

By: /s/ James E. Brown

James E. Brown
President and Chief Executive Officer

## **INDEX TO EXHIBITS**

Exhibit	
Number	Description

99.1 Press Release of DURECT Corporation dated March 16, 2009